---
title: "PepGen Inc. (PEPG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PEPG.US.md"
symbol: "PEPG.US"
name: "PepGen Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:10:45.377Z"
locales:
  - [en](https://longbridge.com/en/quote/PEPG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PEPG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PEPG.US.md)
---

# PepGen Inc. (PEPG.US)

## Company Overview

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.pepgen.com](https://www.pepgen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.24 | 197 | - | - | - |
| PB | 0.71 | 62 | 2.71 | 1.97 | 0.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Underweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.38 |
| Highest Target | 20.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PEPG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PEPG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PEPG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PEPG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**